On air · 1 of 3 networks
Servier Pharmaceuticals
- servier.us
- US
- 994 employees
Servier Pharmaceuticals’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 28. Watch Servier Pharmaceuticals with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 28 | Checked 29 Oct 2026 | See all 28 ads → | ||
| Meta | Not checked | — | |||
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 9 Oct 2026 | Collect them with the API → |
Servier Pharmaceuticals has 28 live LinkedIn ads. We recorded no Google ads on 9 Oct 2026.
Latest ads
- LINKEDIN · VIDEORecorded 30 Sept 2026
In AML, molecular profiling is not just important, it’s foundational. IDH mutations play a critical role in disease development and treatment decisions. Molecular profiling (including IDH1/2 mutational testing) is now part of the initial workup, per NCCN guidelines, and can meaningfully influence prognosis and therapeutic decisions. On the IDHLearnMore website, we explore how timely, high-quality testing can reduce uncertainty and streamline patient care. I encourage you to take a look and learn how diagnostic clarity can help transform AML care: https://lnkd.in/gKcJ32up
- LINKEDIN · IMAGERecorded 30 Sept 2026
To develop effective AML therapies, we must first decode the disease at the molecular level. IDH mutations are among the early genetic changes that can alter cell metabolism and drive disease progress in AML and MDS. On IDHLearnMore website, you’ll find in-depth explanations of mutation impact and visualizations that help translate biology into actionable insight. I encourage colleagues in clinical practice to visit: https://lnkd.in/eQfYU_wm
- LINKEDIN · IMAGERecorded 30 Sept 2026
IDH mutations play a key part in the disease process in a number of cancers, including acute myeloid leukemia (AML).
- LINKEDIN · VIDEORecorded 30 Sept 2026
Molecular testing in acute myeloid leukemia (AML) is critical to helping patients and physicians make informed treatment decisions. Learn why.
- LINKEDIN · CAROUSELRecorded 30 Sept 2026
Myth or Fact: IDH mutations are rare and clinically irrelevant in AML. Scroll below to reveal the answer, and explore more.
- LINKEDIN · IMAGERecorded 30 Sept 2026
Molecular testing can help inform AML care. Advances in mutational testing have improved access to molecular data from diagnosis, risk stratification and clinical decision-making.
6 of 28 adsSign up to see every Servier Pharmaceuticals ad, filter by format and date, and get alerts on new ones.
See all 28 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.